Crinetics Pharmaceuticals (CRNX) Current Leases (2021 - 2026)

Crinetics Pharmaceuticals' Current Leases history runs 6 years deep, the most recent figure standing at $6.5 million for Q1 2026.

• On a quarterly basis, Current Leases fell 5.04% year-over-year to $6.5 million in Q1 2026; TTM through Mar 2026 was $6.5 million, a 5.04% decrease from a year earlier, with the FY2025 full-year figure at $6.5 million, down 9.27% from the prior year.
• Current Leases grew to $6.5 million in Q1 2026 per CRNX's latest filing, from $6.5 million in the prior quarter.
• Across five years, Current Leases topped out at $7.4 million in Q2 2024 and bottomed at $1.0 million in Q3 2022.
• The 5-year median for Current Leases is $6.4 million (2025), against an average of $4.9 million.
• Across the five-year window, Current Leases jumped 571.33% in 2024 and dropped 13.11% in 2025, its largest moves.
• Year by year, Current Leases stood at $1.1 million in 2022, then surged by 297.05% to $4.2 million in 2023, then jumped by 71.39% to $7.2 million in 2024, then slipped by 9.27% to $6.5 million in 2025, then grew by 0.72% to $6.5 million in 2026.
• Per Business Quant, the three latest CRNX Current Leases figures stand at $6.5 million (Q1 2026), $6.5 million (Q4 2025), and $6.4 million (Q3 2025).